Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial03: Dato-DXd plus platinum vs gemcitabine plus platinum in urothelial carcinoma after EV + pembrolizumab
jRCT2061250062Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in transitional cell carcinoma (TCC) and bladder cancer (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Overall Response Rate - Part A (Phase 2), Progression-Free Survival (BICR) - Part B (Phase 3) and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on jRCT2061250062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250062.